Featured Content

Navigating the Costs of Chronic Myeloid Leukemia: A Glimpse Into the Future

The cost of treating CML can be crippling, and it's unclear whether future approvals or policies will improve the financial toxicity associated with the disease.

ASCO Advance of the Year: Immunotherapy 2.0

The American Society of Clinical Oncology (ASCO) named Immunotherapy 2.0 the "advance of the year."

Do Clinical Trials Overstate New Cancer Drugs' Survival Benefits?

Experts disagree about whether success in clinical trials translates to success in real world treatment settings.

Ponatinib: Black Box Warning and Drug Interactions

If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit analysis before deciding whether to continue treatment.

TKI Discontinuation and Chronic Myeloid Leukemia

TKIs offer the possibility of durable responses for patients with CML, though it is unclear whether discontinuation is feasible.

Chronic Myeloid Leukemia Resources

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters